Clinical Trials
49 trialsSTARTRK-2
Hoffmann-La Roche
Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors
National Cancer Institute (NCI)
TRIDENT-1
Turning Point Therapeutics, Inc.
Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial
National Cancer Institute (NCI)
LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas
M.D. Anderson Cancer Center
18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection
National Institutes of Health Clinical Center (CC)
iCaRe2
University of Nebraska
ANTARES
Instituto do Cancer do Estado de São Paulo
STARTRK-NG
Hoffmann-La Roche
A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations
Endeavor Biomedicines, Inc.
IDOV-Immune for Advanced Solid Tumors
ViroMissile, Inc.
Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types
University of Florida
LIBRETTO-121
Eli Lilly and Company
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
Tanabe Pharma America, Inc.
Pan-MSI-ACSE
UNICANCER
Ivonescimab in the Treatment of Multiple Advanced Tumors
Fudan University
Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers
Jonsson Comprehensive Cancer Center
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers
University of Pittsburgh
Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors
PharmaMar
HTL0039732 in Participants With Advanced Solid Tumours
Cancer Research UK
Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors
Hutchmed
Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction
National Cancer Institute (NCI)
ROOT
Taproot Health
Milademetan in Advanced/Metastatic Solid Tumors
Rain Oncology Inc
RaC-Ad
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
A Multi-Center, Open-Label Study of Surufatinib (HMPL-012) in Patients With Advanced Solid Tumors
Hutchmed
Simultaneous Hyperpolarized [1-13C]Pyruvate and 18F-FDG PET/MRS in Cancer Patients
Rigshospitalet, Denmark
AcSé
UNICANCER
HETERERO
Charite University, Berlin, Germany
ALpha-T
Hoffmann-La Roche
REGOMUNE
Institut Bergonié
PPB
Children's National Research Institute
Open Label Extension Study of Conatumumab and Ganitumab (AMG 479)
Amgen
PIONEER
SpeciCare
Safety Study of Dacarbazine and Bortezomib in Melanoma and Soft Tissue Sarcoma
Virginia Commonwealth University
Radiolabeled Octreotide in Treating Children With Advanced or Refractory Solid Tumors
University of Iowa
B-Receptor Signaling in Cardiomyopathy
Stanford University
Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors
National Cancer Institute (NCI)
Surgery With or Without Chemotherapy in Treating Patients With Soft Tissue Sarcoma
European Organisation for Research and Treatment of Cancer - EORTC
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
INSYS Therapeutics Inc
Seneca Valley Virus-001 and Cyclophosphamide in Treating Young Patients With Relapsed or Refractory Neuroblastoma, Rhabdomyosarcoma, or Rare Tumors With Neuroendocrine Features
Children's Oncology Group
Combination Chemotherapy and Tamoxifen in Treating Patients With Solid Tumors
National Cancer Institute (NCI)
A Study of ChemoFx® Chemoresponse Assay in Solid Tumors - ChemoFx® Registry Study
Precision Therapeutics
Surgery With or Without Combination Chemotherapy in Treating Patients With Lung Metastases From Soft Tissue Sarcoma
European Organisation for Research and Treatment of Cancer - EORTC
Tumor Necrosis Factor in Patients Undergoing Surgery for Primary Cancer or Metastatic Cancer
National Institutes of Health Clinical Center (CC)
Continuous Hyperthermic Peritoneal Perfusion (CHPP) With Cisplatin for Children With Peritoneal Cancer
M.D. Anderson Cancer Center
MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma
National Institutes of Health Clinical Center (CC)
Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-PP) for Patients With Advanced Cancer.
Mannkind Corporation
11C-Acetate PET/CT Non-FDG-Avid Tumors
Tel-Aviv Sourasky Medical Center